| Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff |
I'm downgrading Kymera to 'Hold' due to slow clinical progress, pipeline uncertainty, and lack of near-term catalysts despite strong cash position. Kymera's unique focus on immunology with oral protein degraders offers potential, but faces entrenched competitors and unproven clinical efficacy. Sanofi's advancement of KT-474 is positive, but may be more about testing protein degradation's threat to Dupixent than a strong endorsement. |
seekingalpha.com |
2025-05-14 20:59:27 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript |
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Veronica Campbell - Senior Director of Immunology Conference Call Participants Jeet Mukherjee - BTIG Marc Frahm - TD Cowen Eliana Merle - UBS Securities Sudan Loganathan - Stephens Vikram Purohit - Morgan Stanley Eric Joseph - JPMorgan Faisal Khurshid - Leerink Partners Michael Schmidt - Guggenheim Andy Chen - Wolfe Research Kalpit Patel - B. Riley Justine Koenigsberg Good morning and welcome to Kymera's Immunology Innovation Day, our virtual event to introduce our next immunology program, IRF5. |
seekingalpha.com |
2025-05-10 01:37:14 |
Czytaj oryginał (ang.) |
| Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging |
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028. |
zacks.com |
2025-05-09 18:30:19 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates |
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago. |
zacks.com |
2025-05-09 13:10:39 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases |
IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug |
globenewswire.com |
2025-05-09 11:01:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update |
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clinical development to focus our team and incremental financial resources on the rapidly progressing STAT6 program Well-capitalized with $775 million in cash as of March 31, 2025, now providing an extended runway into the first half of 2028 Company to hold video conference call and webcast today at 10:00 a.m. ET WATERTOWN, Mass. |
globenewswire.com |
2025-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference |
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT. |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Why Kymera Therapeutics Stock Crushed it This Week |
According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (KYMR -0.86%) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile biotech sector. |
fool.com |
2025-04-25 22:03:20 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader |
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe atopic dermatitis (AD). |
globenewswire.com |
2025-04-22 11:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? |
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-04-10 15:10:38 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer |
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company. |
globenewswire.com |
2025-04-09 11:00:00 |
Czytaj oryginał (ang.) |
| Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus |
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027. |
zacks.com |
2025-02-28 16:16:29 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript |
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Andy Chen - Wolfe Research Paul Jeng - Guggenheim Ron Feiner - JPMorgan Jeff Jones - Oppenheimer Brad Canino - Stifel Marc Frahm - TD Cowen Ellie Merle - UBS Securities Parth Patel - Morgan Stanley Kripa Devarakonda - Truist Securities Eva Fortea-Verdejo - Wells Fargo Eric Wong - Goldman Sachs Jeet Mukherjee - BTIG Sudan Loganathan - Stephens Operator Good day everyone. My name is Megan and I will be your conference operator today. |
seekingalpha.com |
2025-02-27 16:48:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates |
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2025-02-27 11:20:36 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Participate in Upcoming March Investor Conferences |
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Participate in Upcoming February Investor Conferences |
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: |
globenewswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| Kymera Provides Pipeline Objectives for 2025, Stock Gains |
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027. |
zacks.com |
2025-01-15 16:31:10 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? |
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-01-15 12:41:31 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs |
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively KT-295 (TYK2) to advance into Phase 1 testing in 2Q25 with data expected in late 2025 KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD ongoing, with completion expected in 1H26 and mid-2026, respectively Novel oral immunology program with a first-in-class development candidate to be disclosed in 1H25 Well-capitalized with $850 1 million in cash and runway into mid-2027 Kymera to present its 2025 outlook at J.P. Morgan Annual Healthcare Conference on Tuesday, January 14, 2025, at 9:00 a.m. |
globenewswire.com |
2025-01-14 09:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 |
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2025. |
globenewswire.com |
2025-01-07 09:00:00 |
Czytaj oryginał (ang.) |
| Kymera: Protein Degradation Could Drive Dupixent-Like Value |
Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for immuno-inflammatory disorders, shows promise with Phase 1 data expected in the first half of 2025. The company has $911 million in cash, sufficient to fund operations into mid-2027, covering key milestones and pipeline developments. |
seekingalpha.com |
2024-12-07 03:07:59 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Participate in Upcoming December Investor Conferences |
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Participate in Upcoming November Investor Conferences |
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: |
globenewswire.com |
2024-11-05 09:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript |
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - CFO Conference Call Participants Marc Frahm - TD Cowen Kalpit Patel - B. Riley Alexei Siniakov - Truist Securities Brad Canino - Stifel Nicolaus Gospel Enyindah-Asonye - Morgan Stanley Kelly Shi - Jefferies Jeff Jones - Oppenheimer Eric Joseph - J.P. |
seekingalpha.com |
2024-11-03 18:11:28 |
Czytaj oryginał (ang.) |
| Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus |
Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027. |
zacks.com |
2024-11-01 13:20:33 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates |
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago. |
zacks.com |
2024-10-31 11:40:29 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update |
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 |
globenewswire.com |
2024-10-31 09:30:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-24 15:05:34 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases |
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases |
globenewswire.com |
2024-10-24 11:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 |
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET. |
globenewswire.com |
2024-10-23 11:15:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium |
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data from its innovative TPD platform will be presented across three poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The presentations include new data on its preclinical biomarker-based approach for KT-253, its MDM2 degrader. |
globenewswire.com |
2024-10-23 11:00:00 |
Czytaj oryginał (ang.) |
| Kymera's IND Application for STAT6 Degrader Gets FDA Clearance |
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA. |
zacks.com |
2024-10-10 14:33:18 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader |
KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases |
globenewswire.com |
2024-10-09 11:00:00 |
Czytaj oryginał (ang.) |
| Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors |
Kymera Therapeutics' innovative TPD technology degrades disease-causing proteins, with promising candidates like KT-474 and KT-621 targeting large TAMs in immunology and oncology. The company's approach leverages the body's proteasome system to degrade harmful proteins. This could lead to safer and less invasive treatments. Kymera's cash runway of approximately 4.9 years is expected to support the advancement of its pipeline until 2027. |
seekingalpha.com |
2024-10-06 18:58:27 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress |
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease |
globenewswire.com |
2024-09-25 11:00:00 |
Czytaj oryginał (ang.) |
| Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? |
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-06 16:37:54 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics to Participate in Upcoming September Investor Conferences |
WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: |
globenewswire.com |
2024-08-28 11:00:00 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares |
WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 2,830,533 shares of its common stock, which includes 828,220 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of its common stock in the offering. The shares of common stock were sold at a public offering price of $40.75 per share and the pre-funded warrants were sold at a public offering price of $40.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering were approximately $258.75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera. |
globenewswire.com |
2024-08-21 15:15:00 |
Czytaj oryginał (ang.) |
| Kymera (KYMR) to Raise $225 Million Through Offering of Shares |
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering. |
zacks.com |
2024-08-20 18:05:46 |
Czytaj oryginał (ang.) |
| Kymera Therapeutics Announces Pricing of $225 Million Public Offering |
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $40.75 per share and the pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 828,220 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on August 21, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-08-20 02:45:00 |
Czytaj oryginał (ang.) |